metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
la/mBC - HR positive - L2 - all population breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2) la/mBC - HR positive - L2 - all population
versus fulvestrant
	buparlisib plus fulvestrant
	BELLE-2 (full population), 2017 Lancet Oncol 2017; 18:904-916-. Eur J Cancer 2018; 103:147-154-. NCT01610284	RCT	la/mBC - HR positive - L2 - all population	buparlisib plus fulvestrant	placebo plus fulvestrant	Postmenopausal women (>=18yr), with histollogically confirmed HR-positive and HER2-negative inoperable locally advanced or metastatic breast cancer (with progession on or after aromatase ihnibitor treatment)	576 / 571	low	conclusif	inconclusive 13 % decrease in deaths (OS) (PE) demonstrated 22 % decrease in progression or deaths (PFS) (PE)
versus pegylated liposomal doxorubicin and cyclophosphamide
	nivolumab plus ipilimumab, pegylated liposomal doxorubicin and cyclophosphamide
	ICON, 2024 J Immunother Cancer 2024; 12:1240-1247-. J Transl Med 2020; 18:269-. NCT03409198	RCT	la/mBC - HR positive - L2 - all population	Ipilimumab plus nivolumab plus PLD plus cyclophosphamide	PLD plus cyclophosphamide	Patients with HR mBC starting first-/second- line chemotherapy (chemo)	49 / 33	some concern	inconclusive	inconclusive 6 % decrease in progression or deaths (PFS),progression or deaths (PFS) (PE) The addition of ipi/nivo to chemotherapy increased toxicity without improving efficacy. Ipi/nivo administered sequentially to chemotherapy was tolerable and induced clinical responses.